pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics is a pharma organization headquartered in New Haven, USA. It trades on NYSE under ticker BTAI. Primary therapeutic focus areas include Agitation, Agitation,Psychomotor, Alcohol Use Disorder (AUD), Sc
555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US HQ
2017 Founded
56 Employees
Public company Type
BTAI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Phase 1 · small molecule · Alcohol Use Disorder (AUD)
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg for Alcohol Use Disorder (AUD) is a Phase 1 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code AS210006-A08
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioXcel Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Alcohol Use Disorder (AUD)
- Status
- active
- Trials
- 1